Supplement guide · Anxiety and sleep

Kava: Calm, Sleep and Liver Risk

📄 22 PubMed citations

Kava lowered anxiety scores in several short trials, then failed to beat placebo in a 16-week trial of 171 people. It also carries a rare but documented risk of serious liver injury.

🔬 Kava pages usually pick a side: Pacific tradition with no real risk, or a liver toxin that should be banned. The PubMed record supports neither. We sorted the anxiety trials by length and size, because the result changes between the short trials and the 16-week one. We kept tablets at medicinal doses separate from the large volumes drunk at traditional sessions, since the cognition and driving data differ between them. The liver section reports what regulators acted on in 2002 and what the later case reviews concluded about cause.
645
Participants in the 11 trials of the Cochrane kava review
171
People with GAD in the 16-week trial where kava did not beat placebo
11
Kava users with liver failure who needed a transplant, CDC 2002
Sunlit armchair with a yellow throw blanket beside a window, with light through blinds casting stripes on the wooden floor
Photo: Sergiy Galyonkin · CC BY-SA · source

Still logging injections in your Notes app?

A notes thread can't show a missed day at a glance, because it's a list, not a calendar. A printed log can. Your compounds and dates filled in: injection log, weekly schedule, dated calendar. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →

How Does Kava Work in the Brain?

🧪
Kavalactones on GABA-A receptors

Kavain, the main kavalactone, boosted the response of every human GABA-A receptor type tested in frog egg cells. Flumazenil, which blocks the benzodiazepine site, did not stop the effect, so kavain does not work through the benzodiazepine binding site (kavain GABA-A receptor study, PMID 27332705).

🧠
Brain GABA in people with GAD

In 37 adults with generalized anxiety disorder, 8 weeks of kava at 120 mg kavalactones twice daily lowered GABA in the dorsal anterior cingulate cortex compared with placebo (p = 0.049). The drop was not linked to changes in anxiety scores (kava dACC GABA neuroimaging study, PMID 37960239).

⚖️
One dose: no fog, and no calm

A single 180 mg kavalactone dose had no negative effect on cognition in 22 anxious adults, while 30 mg of oxazepam reduced alertness. The same kava dose also failed to reduce anxiety acutely in these first-time users (acute kava and oxazepam study, PMID 22311378).

💊
Drug metabolism, in rats

In rats, a kava (Piper methysticum) extract raised peak blood levels of the sedative midazolam 4-fold by blocking cytochrome P450 3A (CYP3A) metabolism in the gut. This was an animal study (valerian and kava CYP3A study, PMID 39013429).

What the Data Shows

3-week crossover, elevated anxiety
Hamilton Anxiety score fell 9.9 points on aqueous kava vs 0.8 on placebo in the first phase; 60 adults, 250 mg kavalactones a day (Kava Anxiety Depression Spectrum Study; PMID 19430766)
-9.9 vs -0.8
Cochrane pooled result, 6 trials
Hamilton Anxiety score 5.0 points lower than placebo (95% CI 1.1 to 8.8), 345 people (Cochrane kava extract for anxiety review; PMID 12535473)
5.0 points
GAD meta-analysis, 2018
Modest effect of -3.24 points that missed significance (95% CI -6.65 to 0.17, P = 0.059) (complementary treatments for GAD meta-analysis; PMID 29508154)
-3.24, P = 0.059
Network meta-analysis, all anxiety
Effective overall at -2.46 points, but -0.17 in generalized anxiety disorder (medicinal herbs for anxiety network meta-analysis; PMID 35378276)
-2.46 / -0.17 GAD
16-week trial, diagnosed GAD
No significant difference; the relative reduction favoured placebo by 1.37 points (p = 0.25), 171 people (16-week kava GAD trial; PMID 31813230)
placebo +1.37

Daily Dosing Schedule

TimeCompounds
Generalized anxiety, 6 weeksAqueous kava extract at 120 mg kavalactones a day, raised to 240 mg in non-responders (6-week kava GAD trial, PMID 23635869).
Generalized anxiety, 16 weeks120 mg kavalactones twice a day from an aqueous root extract. This dose did not beat placebo (16-week kava GAD trial, PMID 31813230).
Elevated anxiety, 3 weeksFive tablets a day supplying 250 mg kavalactones from an aqueous extract (Kava Anxiety Depression Spectrum Study, PMID 19430766).
Sleep problems with anxiety200 mg of the kava extract WS 1490 daily for 4 weeks (WS 1490 sleep disturbance trial, PMID 14706720).
Proposed medicinal ceiling250 mg kavalactones a day or less, from a water extract of peeled rhizomes and roots of a noble cultivar (six-point kava standardization plan, PMID 21112196).

Key Takeaways

What We Know
  • A Cochrane review of 11 trials with 645 participants found that kava extract lowered Hamilton Anxiety scores by 5.0 points more than placebo across 6 pooled trials, with mild, transient and infrequent adverse events over 1 to 24 weeks (PMID 12535473).
  • In a 6-week trial in generalized anxiety disorder, kava reduced anxiety more than placebo (Cohen d = 0.62), and 26% of the kava group were in remission vs 6% on placebo (PMID 23635869). Kava did not differ from placebo on liver function tests, withdrawal or addiction in that trial (PMID 23348842).
  • In the 16-week trial of 171 people with generalized anxiety disorder, kava did no better than placebo: 17.4% remitted on kava vs 23.8% on placebo (PMID 31813230).
  • In 61 patients with sleep problems tied to anxiety, 200 mg a day of the extract WS 1490 for 4 weeks improved sleep quality and how rested people felt after sleep compared with placebo (PMID 14706720).
  • A single medicinal dose of 180 mg kavalactones did not impair cognition (PMID 22311378) or simulated driving, while 30 mg of oxazepam slowed braking reaction time (PMID 23259514).
  • By 2002, 11 kava users in Germany, Switzerland and the United States had liver failure and underwent liver transplantation, and the FDA issued a consumer advisory on March 25, 2002 (PMID 12500906).
  • Liver injury has also followed traditional water-based kava drinks in New Caledonia, Australia, the USA and Germany, so the solvent alone does not explain it (PMID 21801196).
What We Don't Know
  • Whether kava helps diagnosed generalized anxiety disorder. The two GAD trials disagree (PMID 23635869, PMID 31813230), and a network meta-analysis found kava effective for anxiety overall but possibly ineffective in GAD (PMID 35378276).
  • What causes the liver injury. Reviews point to poor quality raw material (PMID 21801196), which may have been contaminated after harvest by mould toxins such as aflatoxins, a question that still needs study (PMID 21377431). Pipermethystine was not detectable in Western extracts, and flavokavain B was present at levels too low to injure the liver in animal experiments (PMID 21377431).
  • Who is most at risk. In most of 14 patients with suspected kava liver injury, the risk factors included overdose, prolonged treatment, and taking kava with synthetic drugs or other supplements (PMID 20720265).
  • What longer use does. Over 16 weeks, liver function test abnormalities were more frequent on kava, although no participant met criteria for herb-induced liver injury, and poorer memory and tremor were reported more often on kava (PMID 31813230).
  • What heavy traditional use does over years. In an Arnhem Land community study of 101 adults, kava users had more skin changes (dermopathy), higher GGT and alkaline phosphatase, and lower lymphocyte counts, with no difference on neurocognitive tests (PMID 12895162).
  • Whether you can drive after a long kava session. After about 6 hours and 3.6 L of kava, drinkers showed impaired temporal order judgement (PMID 35151837), and four Iowa drivers who reported kava use showed poor driving and signs of intoxication (PMID 31305953).

Frequently Asked Questions

Is kava bad for your liver?

It can be, rarely. A 2002 CDC report counted 11 kava users in Germany, Switzerland and the United States who had liver failure and needed a transplant (kava hepatic toxicity report, PMID 12500906). A later clinical review of 14 cases named overdose, prolonged treatment and taking kava with other drugs or supplements as risk factors, and pointed to poor raw material quality (kava hepatotoxicity clinical review, PMID 20720265). In the 16-week trial, liver test abnormalities were more frequent on kava, but no participant met criteria for herb-induced liver injury (16-week kava GAD trial, PMID 31813230).

Does kava work for anxiety?

In short trials, usually. The Cochrane review of 11 trials found Hamilton Anxiety scores fell 5.0 points more on kava than on placebo (Cochrane kava extract review, PMID 12535473). In a 16-week trial in 171 people with generalized anxiety disorder, kava did not beat placebo (16-week kava GAD trial, PMID 31813230).

Does kava help you sleep?

One trial says yes for sleep problems that come with anxiety. In 61 patients, 200 mg a day of the kava extract WS 1490 for 4 weeks improved sleep quality and how rested people felt after sleep compared with placebo (WS 1490 sleep disturbance trial, PMID 14706720).

Does kava affect focus, memory or driving?

A single medicinal dose did not measurably impair them. A 180 mg kavalactone dose had no negative effect on cognition, while oxazepam reduced alertness (acute kava and oxazepam study, PMID 22311378), and the same dose did not impair simulated driving (medicinal kava dose driving study, PMID 23259514). Daily use is different: over 16 weeks at 120 mg kavalactones twice a day, poorer memory was reported more often on kava than on placebo, 36 vs 23 (16-week kava GAD trial, PMID 31813230). After about 6 hours and 3.6 L at a traditional session, temporal order judgement was impaired (traditional kava cognition and driver fitness study, PMID 35151837).

What is noble kava, and is it safer?

Noble kava means cultivars defined in the Vanuatu Kava Act of December 2002 and described as well tolerated. Liver researchers proposed using a noble cultivar such as Borogu, at least 5 years old at harvest, with peeled rhizomes and roots, water extraction and 250 mg kavalactones a day or less (six-point kava standardization plan, PMID 21112196). That plan is a proposal, and liver injury has also followed traditional water-based kava drinks (Pacific kava paradox review, PMID 21801196).

Peer-Reviewed References

Source 1
Kava extract for treating anxiety
Cochrane Database Syst Rev · 2003
PMID: 12535473
Source 2
Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study
Aust N Z J Psychiatry · 2020
PMID: 31813230
Source 3
Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study
J Clin Psychopharmacol · 2013
PMID: 23635869
Source 4
Kava for the treatment of generalized anxiety disorder RCT: analysis of adverse reactions, liver function, addiction, and sexual effects
Phytother Res · 2013
PMID: 23348842
Source 5
The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum
Psychopharmacology (Berl) · 2009
PMID: 19430766
Source 6
Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial
J Affect Disord · 2004
PMID: 14706720
Source 7
The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study
Hum Psychopharmacol · 2012
PMID: 22311378
Source 8
Does a medicinal dose of kava impair driving? A randomized, placebo-controlled, double-blind study
Traffic Inj Prev · 2013
PMID: 23259514
Source 9
Kava drinking in traditional settings: Towards understanding effects on cognitive function
Hum Psychopharmacol · 2020
PMID: 32064691
Source 10
The impact of traditional kava (Piper methysticum) use on cognition: Implications for driver fitness
J Ethnopharmacol · 2022
PMID: 35151837
Source 11
Cases of Kava Impairment in Iowa Drivers
J Forensic Sci · 2019
PMID: 31305953
Source 12
Hepatic toxicity possibly associated with kava-containing products--United States, Germany, and Switzerland, 1999-2002
MMWR Morb Mortal Wkly Rep · 2002
PMID: 12500906
Source 13
Kava hepatotoxicity--a clinical review
Ann Hepatol · 2010
PMID: 20720265
Source 14
Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited
Br J Clin Pharmacol · 2012
PMID: 21801196
Source 15
Kava hepatotoxicity solution: A six-point plan for new kava standardization
Phytomedicine · 2011
PMID: 21112196
Source 16
Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits
Dig Liver Dis · 2011
PMID: 21377431
Source 17
Health effects of kava use in an eastern Arnhem Land Aboriginal community
Intern Med J · 2003
PMID: 12895162
Source 18
Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism
PLoS One · 2016
PMID: 27332705
Source 19
Neuroimaging Insights: Kava's (Piper methysticum) Effect on Dorsal Anterior Cingulate Cortex GABA in Generalized Anxiety Disorder
Nutrients · 2023
PMID: 37960239
Source 20
Complementary and Alternative Medicine Treatments for Generalized Anxiety Disorder: Systematic Review and Meta-analysis of Randomized Controlled Trials
Adv Ther · 2018
PMID: 29508154
Source 21
Medicinal herbs for the treatment of anxiety: A systematic review and network meta-analysis
Pharmacol Res · 2022
PMID: 35378276
Source 22
Evaluation of the Effects of Extracts Containing Valeriana officinalis and Piper methysticum on the Activities of Cytochrome P450 3A and P-Glycoprotein
Planta Med · 2024
PMID: 39013429
Ebook
The Complete Peptide Protocol Guide

67-page guide: protocols, dosing, sourcing. Everything in one place.

Get the guide: $19 (normally $29) → The Peptide Buyer’s Playbook ($19) All ebooks & guides →
Disclaimer

Educational purposes only. Not medical advice.

Kava is sold in the US as a dietary supplement, not an FDA-approved drug. Talk to a clinician before using it if you have liver disease, take prescription medicines or sedatives, drink alcohol regularly, or are pregnant.

📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.